🧪
hypothesis

m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Promotes Lewy Pathology

Hypothesis

m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Promotes Lewy Pathology

N6-methyladenosine (m6A) hypermethylation of SNCA mRNA in substantia nigra dopaminergic neurons stabilises the transcript, increases alpha-synuclein protein levels, and lowers the concentration threshold for protein aggregation into Lewy.
🧬 SNCA🩺 parkinson🎯 Composite 66%💱 $0.52▼0.4%open
neurodegeneration
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.76 (15%) Evidence 0.45 (15%) Novelty 0.72 (12%) Feasibility 0.65 (12%) Impact 0.80 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.35 (8%) 0.662 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite66%

🧪 Overview

N6-methyladenosine (m6A) hypermethylation of SNCA mRNA in substantia nigra dopaminergic neurons stabilises the transcript, increases alpha-synuclein protein levels, and lowers the concentration threshold for protein aggregation into Lewy bodies. Pharmacological inhibition of METTL3 (the primary m6A writer) should reduce SNCA mRNA stability, lower alpha-synuclein protein levels, and decrease aggregation in PD model neurons.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["METTL3 m6A Writer Complex<br/>Substantia Nigra Dopaminergic Neurons"]
    B["N6-Methyladenosine Hypermethylation<br/>SNCA mRNA Specific Sites"]
    C["SNCA Transcript Stabilized<br/>Reduced mRNA Turnover Rate"]
    D["Alpha-Synuclein Protein Levels Rise<br/>Above Aggregation Threshold"]
    E["Lewy Body Nucleation<br/>Lower Critical Concentration"]
    F["Lewy Body Pathology Progression<br/>Dopaminergic Neuron Loss"]
    G["Parkinson Disease Neurodegeneration"]
    H["METTL3 Pharmacological Inhibition<br/>SNCA mRNA Destabilization Strategy"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    H -.->|"reduce SNCA levels"| B
    style B fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix5 supports0 contradicts
Supports
R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation.
Autophagy2025PMID:40143425medium
Supports
Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy.
Trends Biochem Sci2021PMID:33323315medium
Supports
MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease.
Mol Neurodegener2023PMID:38041169medium
Supports
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
Autophagy2022PMID:35287553medium
Supports
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
JCI Insight2021PMID:33682798medium
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — SNCA

🧬 PDB 1XQ8 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SNCA →

No DepMap CRISPR Chronos data found for SNCA.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0766
Events (7d)
1
Price History
▼0.4%

💾 Resource Usage

LLM Tokens
492,603
$1.8154
API Calls
302
Total Cost
$1.8154
View on SciDEX ↗